Table 2.
Oral glucose tolerance test, homeostasis model assessment-insulin resistance, area under the curve and lipid profile in Group A (spironolactone) and Group B (spironolactone and dietary induced weight-loss) at baseline and alter treatment
| Group A (n=5) | Group B (n=7) | |||
|---|---|---|---|---|
|
|
|
|||
| Baseline | After therapy | Baseline | After therapy | |
| Age (years) | 19.8±5 | - | 24±5.7 | - |
| BMI (kg/m2) | 28.6±4.7 | 29±5.4 | 30.3±3.5 | 26.3±3.4* |
| Score FG | 10.6±2.7 | 5.6±2.7 | 9.7±3.3 | 5±2.8 |
| Fasting glucose (mmol/l) | 5.1±0.1 | 4.9±0.6 | 4.8±0.5 | 4.7±0.5 |
| 75-g OGTT 60 min (mmol/l) | 6.7±1.5 | 6.6±1.5 | 6.9±2.9 | 5.4±1.3 |
| 75-g OGTT 120 min (mmol/l) | 5.4±1.3 | 5.2±1.6 | 6±2 | 5±1.4 |
| Fasting insulin (mmol/l) | 18.2±6.8 | 16.4±3.6 | 17.4±3.4 | 13.9±8 |
| 75-g OGTT 60 min (mmol/l) | 73.4±15.5 | 66.6±17.8 | 63±14 | 41.3±24.3* |
| 75-g OGTT 120 min (mmol/l) | 4ó.8±13.3 | 45±21.6 | 32±23.3 | 15.57±6.4 |
| HOMAIR | 4.1±1.5 | 4.2±1.8 | 3.2±0.4 | 1.9±0.6* |
| AUCinsulin | 5880±1592 | 5004±2189 | 6090±3791 | 4500±2120* |
| TG (mmol/l) | 1.5±0.1 | 1.2±0.3* | 1.6±0.1 | 1.2±0.2* |
| TC (mmol/l) | 4.52±0.5 | 4.68±0.8 | 4.45±0.4 | 4.85±0.4 |
| HDL-choIesterol (mmol/l) | 1.16±0.1 | 1.18±0.2 | 1.2±0.1 | 1.2±1.5 |
BMI: Body mass index, TC: Total cholesterol, HDL: High-density lipoprotein, OGTT: Oral glucose tolerance test, HOMAIR: Homeostasis model assessment-insulin resistance, AUC: Area under the curve, TG: Triglycerides, FG: Ferriman-Gallwey, P <0.005